


# Nasal Drug Delivery Symposium

## Current Status and Future Opportunities

9-10 June, 2026, Stockholm, Sweden

### Program

Tuesday 9 June	
12.00 – 13.00	Registration and light lunch
13.00 – 13.10	<b>Welcome</b> Chair: Stefan Ulvenlund, Pentahedron Consulting
13.10 – 13.35	<b>Nose anatomy and physiology in relation to drug administration for local and systemic targets; opportunities, barriers and remaining challenges</b> Per Wollmer, Lunds University
13.35 – 14.00	<b>Nose-to brain - current status and future opportunities</b> Gonçalo Farias, Aptar
14.00 – 14.25	<b>CFD modelling of a nasal spray impingement with and without coating</b> Roven Pinto, FS Dynamics
14.25 – 14.50	<b>Use of anatomically realistic nasal cavity models in in vitro deposition testing – options and challenges</b> Mårten Svensson, Emmace Consulting
14.50 – 15.30	<b>Coffee break</b>  Chair: Jonas Rudén, Orexo
15.30 – 15.55	<b>Aspects on nasal dry powder inhalation – Including the Passive Device ICOone Nasal®</b> Mikael Ekström, Iconovo
15.55 – 16.20	<b>Reliability considerations of rescue medications</b> Maria Sandström, Orexo
16.20-16.45	<b>Liquid Formulations For Nasal Delivery. Are they facing extinction, or will they reincarnate?</b> Stefan Ulvenlund, Pentahedron Consulting
16.45 – 18.30	<b>Mingle and refreshment</b>



# Nasal Drug Delivery Symposium

## Current Status and Future Opportunities

9-10 June, 2026, Stockholm, Sweden

### Program

Wednesday 10 June	
	Chair: Gunilla Petersson, Inhaled Delivery Consulting
09.00 – 09.25	<b>Non-clinical models in intranasal drug development</b> Oskar Hallgren, Truly Labs
09.25 – 09.50	<b>From needle to nose – a nasal epinephrine powder for the treatment of anaphylaxis</b> Jonas Rudén, Orexo
09.50 – 10.30	<b>Coffee break</b>
	Chair: Oskar Hallgren, Truly
10.15 – 10.40	<b>Intranasal vaccination based on a modular Outer Membrane Vesicles platform</b> Mats Lundgren, Abera Bioscience
10.40 – 11.05	<b>A novel peptidomimetic for treatment of respiratory viral infections</b> Niklas Hammarstedt, Pharma Holding
11.05 – 11.30	<b>NOSA Drug Delivery – Unlocking controlled nose-to-brain therapy</b> Adrian Liljefors, NOSA
11.30 – 11.40	<b>Closing</b>